

January 7, 2013

Notice Pertaining to the Joint Distribution of Transdermal Pain Reliever and  
Anti-Inflammatory Mohrus®Pap 30 mg and Mohrus®Pap 60 mg

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu City, Saga Prefecture; President & CEO : Hirotaka Nakatomi; hereinafter: “our company”) is aggressively promoting a capital and business alliance with Yutoku Pharmaceutical Ind. Co., Ltd. (unlisted; Head Office: Kashima City, Saga Prefecture; President and representative director: Keiichi Ueno; hereinafter “Yutoku Pharmaceutical”), an affiliated company by applying the equity method. (Both companies entered into a capital partnership contract on January 17, 2012.)

Now, our company announces that as part of the construction of the capital and business alliance, transdermal pain reliever and anti-inflammatory Mohrus®Pap (Mohrus®Pap 30 mg, Mohrus®Pap 60 mg) produced and distributed by our company will be jointly distributed by two companies from March 2013, in addition to the transdermal pain reliever and anti-inflammatory Mohrus®Tape, which has been jointly distributed.

Our company and Yutoku Pharmaceutical will seek the development and market expansion of the Mohrus brand by the joint distribution of Mohrus®Pap (Mohrus®Pap 30 mg, Mohrus®Pap 60 mg) under the capital and business alliance.

## Reference

### 1. Summary of Mohrus®Pap 30 mg and Mohrus®Pap 60 mg

(1) Non-proprietary Name Ketoprofen

(2)Indications Topical treatment of Pain and inflammation due to the following disorders and symptoms

Osteoarthritis, shoulder periartthritis, tendinitis/tenosynovitis, peritendinitis, humeral epicondylitis (tennis elbow, etc.), muscle pain, swelling and aches caused by external injuries

(3)Dosage and administration Applied to the painful area twice a day

### 2. Future prospect

The influence of this joint distribution on the achievements of our company is expected to be insignificant.